Saturday, February 24, 2024
HomeFunding Amsterdam-based Biotech Company VUS Diagnostics Raises €300K in a Convertible Loan

[Funding alert] Amsterdam-based Biotech Company VUS Diagnostics Raises €300K in a Convertible Loan

Amsterdam-based biotech company VUS Diagnostics raises €300K in a convertible loan from Innovation Fund North Holland (INH). The funds will be used by VUS Diagnostics to build its own laboratory as well as enhance its database and testing platform.

Amsterdam-based biotech company VUS Diagnostics raises €300K in a convertible loan from Innovation Fund North Holland (INH). The funds will be used by VUS Diagnostics to build its own laboratory as well as enhance its database and testing platform.

The goal of this development is to make it feasible to provide individualised treatments to patients in the future. Different gene mutations result in various qualities, but it’s still unclear how some mutations affect diseases.

Read also – Latvia-based SpirulinaNord Secures €600K in Funding

By matching therapeutics to certain cancer characteristics, cancer DNA analysis allows for personalised cancer care. Uncertain variations are found through routine DNA tests, which drives study into their functions and how they react to novel medications.

VUS Diagnostics focuses in comprehensive functional testing of DNA variations, especially those associated with cancer’s DNA repair mechanism. By thoroughly investigating these variants, it addresses the uncertainties around changes in genes and their effect on disease.

Read also – Lithuaniac -based Green Energy Company Green Genius Secures €6.9M in Funding

Wouter Keij, Fund Manager of Innovation Fund North Holland says, “VUS Diagnostics can help develop new effective medicines by creating all kinds of different DNA variants, and at the same time match patients with cancer to the right medicine. You also include a large patient group in which the phenotype of a mutation is currently unknown.”

Co-founder Arne Nedergaard Kousholt says, “After many years working as a basic cancer researcher, it is great to start a new journey and work on transferring lessons learned from research to make an impact on cancer patients.”

About VUS Diagnostics

Arne Nedergaard Kousholt, along with co-founders Zhenya Ivakine, Thomas Thestrup, Philip Schouten, and Simon Grund Sørensen, established VUS Diagnostics in 2022.

Read also – UK-based Globacap Secures $21Million Series B Round Funding

We see a future in which every patient with a hereditary condition will have access to a curative medicine. The therapeutic modalities will keep evolving and be grounded in mechanistic insights from cell biology.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular